OASM
ST
Oasmia Pharmaceutical AB (publ)
Overview
OASM
Symbol
ST
Exchange
About stock

Oasmia Pharmaceutical AB (publ) develops, manufactures, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. The company offers Apealea (paclitaxel micellar) for the treatment of ovarian cancer. Its products portfolio includes Docetaxel micellar, a patented formulation that combines XR-17 with docetaxel, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil, which has completed Phase I clinical trial for the treatment of ovarian cancer.

The company's animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin for the treatment of lymphoma. Oasmia Pharmaceutical AB (publ) was incorporated in 1988 and is headquartered in Solna, Sweden. Address: Gustav III:s Boulevard 46, Solna, Sweden, 169 73

Oasmia Pharmaceutical AB (publ) dividend calculator
Report issue